Senior level moves within drug discovery


There have been a significant number of changes in c-level positions within the industry over the last two months.

Dale Levitzke, Chief Executive Officer, and Curtis Nicholson, Director of Sales for Europe, Middle East, and Africa (EMEA), Sphere Fluidics: Levitzke brings over 25 years’ experience in the life science tools, biopharma, and biotechnology industries. Nicholson also has over two decades of experience, having successfully directed strategic sales initiatives within both small-medium and multinational enterprises.

Ashley Nagle, Chief Business Officer, and Peter Finan, Non-Executive Chairman, Epsilogen: Nagle has moved from a role as VP of Business Development at RemedyBio, and has worked at companies including Lonza Biologics, Almac Sciences and Fulcrum Pharma. Finan has served as Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the UK.

John Milad, Chief Executive Officer, ERS Genomics: Milad brings over 25 years of experience as an executive leader, venture capitalist, and investment banker focused on the life sciences and medical technology sectors, most recently as CEO of Quanta Dialysis Technologies for nearly a decade.

Ryan Gound, President, Labconco: Gound has moved from a role as Labconco’s Executive Vice President, also bringing  prior experience as a management consultant and growth-focused executive leader.

Dr Hazel Jones, Chief Executive Officer, Enhanc3D Genomics: As interim CEO and COO, Dr Jones has overseen the company’s global business operations and held responsibility for executing its strategic vision for commercial and academic partnerships.

Dr Daniel Galbraith, Non-Executive Chair, and David Lawrence, Non-Executive Director, Glen Clova Scientific: Dr Galbraith has over 25 years of contract research experience, previously as Chief Scientific Officer at Solvias. Lawrence has a 30-year track record of building businesses and leading successful financing rounds for life science companies, including the NASDAQ IPO of Valneva where he was CFO.

Dr Matthew Edwards, Senior Vice President of Discovery Sciences, Dr Emma Huang, Vice President of Data Sciences, Dr Adrian Ray, Scientific Advisor, and Dr Scott Turner, Scientific Advisor, Engitix: Joining from Johnson & Johnson, Dr Edwards has developed six clinically-enabled novel therapeutics and has deep immunology and oncology domain expertise. Also from Johnson & Johnson, Dr Huang brings a strong track record of harnessing data science to accelerate the development of novel therapies and solutions for patients. Dr Ray has over two decades of experience in biotech, most recently as Chief Scientific Officer at Third Harmonic Bio, while Dr Turner is currently the Chief Scientific Officer at Arda Therapeutics.

Paul Johnson, Independent Non-Executive Director, Closed Loop Medicine: Johnson is an established leader within the digital healthcare industry, having co-founded Lemonaid Health, one of the first national direct-to-consumer telehealth apps in the US.

Russell Abberley, Vice-President, Association of the British Pharmaceutical Industry (ABPI): Abberley is the General Manager of Amgen UK & Ireland, has over 25 years of life science industry experience, and has served on the ABPI Board since July 2020.

Dr Rafiq Hasan, Non-Executive Director, Exonate: Hasan brings extensive expertise in ophthalmology, specifically within the diabetic eye disease sector, from his years in global pharma.

Kristina Torfgård, Chief Executive Officer, IRLAB Therapeutics: Torfgård has over 30 years of experience from leading roles in the pharmaceutical and biopharmaceutical industry, most recently as CEO of Alzinova.

Scott Minick, Board of Directors, BPGbio: Minick is a veteran biopharma executive and venture capital investor, with a strong track record growing small and mid-sized companies through acquisitions and IPOs.

Marshall Van Beurden, Chief Technology Officer, myTomorrows: Van Beurden previously led the Enterprise Engineering team at Miro and was the Managing Director for the Amazon Web Services (AWS) development center in the Netherlands.

Courtnie Thomas Wilks, Business Development Manager, UK and Europe, Onyx Scientific: Thomas Wilks previously worked for pharmaceutical market intelligence service Citeline, hygiene healthcare and nutrition brand specialist Reckitt, and consumer self-care company Perrigo in a range of commercially focused roles.

Dr Valeria Chichagova, Director of Technology, Newcells Biotech: Following Chichagova’s promotion, Dr Colin Brown will move to become Chief Scientific Officer and Professor Lyle Armstrong, the company’s Co-Founder, will take the role of Scientific Advisor.

Dr Renu Gupta, Chief Medical Officer, and Dr Janet Hammond, Non-Executive Director, Enterprise Therapeutics: Dr Gupta is a physician-scientist, with more than 20 years of experience as a CMO, most recently at Promedior, a member of the Roche Group. Dr Hammond has over 20 years’ experience in the pharmaceutical industry, previously Chief Development Officer at Atea Pharmaceuticals, a Boston-based biotech.

Paul Davie, Chief Business Officer, X-Chem: Davie joins from Schrödinger with an established record of building and growing successful business operations through innovative strategic partnerships that provide unique, data driven solutions and significant year-on-year growth.

Alif Saleh, Chief Executive Officer, xoSim: Previously CEO of Scipher Medicine Corporation, Saleh was named one of the Top 50 Healthcare Technology CEOs in the 2022 The Healthcare Technology Report.

Massimiliano Gnecchi, Chief Scientific Officer, ISCT: Longstanding ISCT member, Gnecchi is currently co-chairing the development of the ISCT Europe 2024 Regional Meeting in Gothenburg, Sweden.

Lydia Seymour, Vice President of People and Culture, CN Bio: Seymour has previously held senior leadership positions at companies including Abcam, TTP Labtech, and Fluidigm Corporation, most recently VP of Human Resources at Evonetix.

Pierre-Alain Ruffieux, Chief Operating Officer, Cytiva: Ruffieux has previously worked as CEO of Lonza, as well as Head of Global Pharma Technical Operations at Roche, where he oversaw pharmaceutical commercial manufacturing and supply chain operations.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free